ClinicalTrials.gg
Active, not recruitingNCT03755804Updated Jun 17, 2026

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

A Phase 2 interventional study of bendamustine and Etoposide in Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 8 sites in United States. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
232
Allocation
Non-randomized
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing bendamustine in Hodgkin Disease — 1 open to participants now, 2 under way, none of them phase 3. bendamustine · Hodgkin Disease.

Enrollment
Largest of 20
232 · median 49
Started
2018
with 2 others
Phase 2
8 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
2 of 20
St. Jude Children's Research Hospital

Among the 20 studies testing bendamustine in Hodgkin Disease, this one has the largest enrollment, is one of 3 that started in 2018, is one of 8 in phase 2, and was the 19th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

1 of the 20 studies testing bendamustine in Hodgkin Disease is open now. Recruiting first, the newest first:

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bendamustine in Hodgkin Disease, or all of them as a file.
02

Study summary

This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.

Read the detailed description

PRIMARY OBJECTIVES

  • To evaluate the efficacy (adequate response) after 2 cycles of BEABOVP (bendamustine substitution for mechlorethamine in the original Stanford V chemotherapy backbone) in low-risk and intermediate-risk patients with classical Hodgkin lymphoma (cHL).
  • To estimate the event-free survival in high-risk patients with classical Hodgkin lymphoma (cHL).

SECONDARY OBJECTIVES

  • To describe the acute hematologic and infectious toxicities of BEABOVP (bendamustine substitution for mechlorethamine in the original Stanford V chemotherapy backbone) in patients with low-risk and intermediate- risk cHL as they relate to transfusion requirements, hematopoietic growth factor support, episodes of febrile neutropenia and hospitalizations, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
  • To describe the acute hematologic, neuropathic, and infectious toxicities of AEPA/CAPDac in patients with high-risk cHL as they relate to transfusion requirements, hematopoietic growth factor support, episodes of grade 3 and 4 sensory or motor neuropathy, episodes of febrile neutropenia and hospitalizations, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
  • To evaluate patterns of failure in irradiated and non-irradiated patients.
  • To estimate the EFS functions of LR and IR patients, and compare with those in previously published studies.
  • To estimate the response rate in HR patients and compare with historical and literature rates.
  • To compare response rates in LR and IR patients with historical and literature rates.
  • To compare the EFS function of HR patients with that in previously published studies.

EXPLORATORY OBJECTIVES

  • To evaluate the plasma pharmacokinetics of bendamustine along with predictors of its variability when used as part of BEABOVP regimen for pediatric cHL patients
  • To explore the patterns and dynamics of T-cell clonality in classical Hodgkin lymphoma
  • To explore the association between TARC, total metabolic tumor volume, stage, risk group and treatment response.
  • To establish next generation sequencing of ctDNA as a reliable method of non-invasively profiling tumor-associated mutations in pediatric patients with HL.
  • To determine if kinetics of ctDNA in patients with pediatric HL during treatment are predictive of outcome.
  • To obtain baseline testing by St. Jude Lifetime Study (SJLIFE) to allow for enhanced survivorship follow-up:

    • Neurologic testing
    • Neurocognitive testing
    • Quantitative brain imaging
    • Polysomnography
    • Cardiovascular testing (valvular testing, arterial elasticity, carotid-femoral pulse wave velocity, orthostatic hypotension, heart rate variability
    • Neuropathy screening
    • Changes in body mass index composition during therapy

Low-risk and Intermediate-risk: Low-risk patients will receive 2 cycles of BEABOVP and Intermediate-risk patients will receive 3 cycles of BEABOVP.

BEABOVP regimen: Patients will receive bendamustine day 1, etoposide day 15, Adriamycin® (doxorubicin) days 1 and 15, bleomycin days 8 and 22, Oncovin® (vincristine) days 8 and 22, vinblastine days 1 and 15, and prednisone two or three times per day every other day of each cycle for a total of 14 days of steroids.

High-risk patients will receive 2 cycles of AEPA and 4 cycles of CAPDac.

AEPA regimen: Patients will receive Adcedris® (brentuximab vedotin) days 1, 8 and 15, etoposide days 1 to 5, prednisone two or three times daily days 1 to 15 and Adriamycin® (doxorubicin) days 1 and 15.

CAPDac regimen: Patients will receive cyclophosphamide days 1 and 8, Adcetris® (brentuximab vedotin) days 1 and 8, prednisone two or three times daily days 1 to 15 and Dacarbazine® (DTIC) days 1 to 3.

Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups.

Steroids will be omitted after 2 cycles for any IR or HR patient with an AR after 2 cycles of therapy.

03

Conditions studied

  • Hodgkin Lymphoma

Keywords

  • Hodgkin Lymphoma
  • Pediatric Cancer
  • Frontline Therapy
  • Response Adapted Therapy
  • Risk Adapted Therapy
04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, previously untreated CD30+ classical HL. (Participants are still eligible if they received limited emergent RT or therapy - maximum of 7 days if within the last month or as approved by PI).
  • Age ≤ 21 years at the time of diagnosis (i.e., participants are eligible until their 22nd birthday) for low-risk and intermediate-risk
  • Age ≤ 25 years at the time of diagnosis (i.e., participants are eligible until their 26th birthday) for high-risk
  • All Ann Arbor stages.

    • Low-Risk: IA, IIA (excluding patients with "E" lesions or mediastinal bulk)
    • Intermediate-Risk: IA or IIA with "E" lesions or bulky mediastinal adenopathy (mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph) and IB, IIIA.
    • High-Risk: IIB, IIIB, IV
  • Adequate renal function based on ≥ 70 ml/min/1.73m2 OR serum creatinine adjusted for age and gender as follows: Age 1 to \< 2 years: maximum serum creatinine 0.6 mg/dL for males and 0.6 mg/dL for females, Age 2 to \< 6 years: maximum serum creatinine 0.8 mg/dL for males and 0.8 mg/dL for females, Age 6 to \< 10 years: maximum serum creatinine 1 mg/dL for males and 1 mg/dL for females, Age 10 to \< 13 years: maximum serum creatinine 1.2 mg/dL for males and 1.2 mg/dL for females, Age 13 to \< 16 years: maximum serum creatinine 1.5 mg/dL for males and 1.4 mg/dL for females, Age ≥16 years: maximum serum creatinine 1.7 mg/dL for males and 1.4 mg/dL for females
  • Adequate hepatic function (total ≤ 1.5 x for age, and /ALT ≤ 2.5 x ULN for age).
  • Adequate hematologic criteria at baseline, unless secondary to Hodgkin disease diagnosis

    • (ANC) ≥1000/µL
    • ≥ 75,000/µL
  • Adequate cardiac function defined as shortening fraction of ≥ 27% by echocardiogram or , unless decreased function is due to large mediastinal mass or effusion related to HL.
  • Adequate pulmonary function defined as no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 92% on room air unless secondary to a large mediastinal mass or effusion related to HL.
  • Female participant who is post-menarchal must have a negative urine or serum pregnancy test.
  • Female or male participant of must agree to use an effective method throughout duration of study treatment.

Exclusion criteria

Exclusion Criteria:

  • CD30 negative HL.
  • Has received prior therapy for Hodgkin lymphoma
  • Inadequate organ function
  • High-risk participants with a history of ≥ grade 2 peripheral neuropathy or any active neurologic disease that would impede the ability to assess neurologic toxicities.
  • Inability or unwillingness of research participant or legal guardian / representative to give written .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    Low-Risk

    Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.

    Drug: bendamustine · Drug: Etoposide · Drug: Doxorubicin · Drug: Bleomycin · Drug: Vincristine · Drug: Vinblastine · Drug: Prednisone · Drug: Filgrastim · Other: Quality of Life Measurements · Radiation: Radiotherapy

  • Experimental
    Intermediate-Risk

    Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.

    Drug: bendamustine · Drug: Etoposide · Drug: Doxorubicin · Drug: Bleomycin · Drug: Vincristine · Drug: Vinblastine · Drug: Prednisone · Drug: Filgrastim · Other: Quality of Life Measurements · Radiation: Radiotherapy

  • Experimental
    High-Risk

    Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements may be done.

    Drug: Etoposide · Drug: Doxorubicin · Drug: Prednisone · Drug: Filgrastim · Drug: Brentuximab Vedotin · Drug: Cyclophosphamide · Drug: DTIC · Other: Quality of Life Measurements · Radiation: Radiotherapy

Interventions

  • Given intravenously (IV)

    Also known as: TREANDA (R)

  • Given intravenously (IV)

    Also known as: VP-16, Vepeside

  • Given intravenously (IV)

    Also known as: Adriamycin (R)

  • Given intravenously (IV)

    Also known as: Blenoxane (R)

  • Given intravenously (IV)

    Also known as: Oncovin (R)

  • Given intravenously (IV)

    Also known as: Velban (R)

  • Given orally (PO)

    Also known as: Prednisolone

  • Given subcutaneously (SQ) or IV

    Also known as: Neupogen (R)

  • Given intravenously (IV)

    Also known as: Adcetris

  • Given intravenously (IV)

    Also known as: Cytoxan (R)

  • DrugDacarbazineStudies of DacarbazineDacarbazine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given intravenously (IV)

    Also known as: DACARBAZINE (R), Dimethyl Triazeno Imidazole Carboximide

  • OtherQuality of Life Measurements

    Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.

    Also known as: Quality of Life Measurements (QOL)

  • RadiationRadiotherapy

    Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.

    Also known as: radiation therapy, irradiation

06

What researchers measure

Primary outcomes

  1. Response rate of adequate response

    The 70 evaluable low-risk patients enrolled will be evaluated for this objective.

    Time frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment

  2. Response rate of adequate response

    The 65 evaluable intermediate-risk patients enrolled will be evaluated for this objective

    Time frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment

  3. Event-free survival

    Time to event defined as relapse, progression or death. The 115 evaluable high-risk patients participants enrolled will be evaluated for this objective.

    Time frame: From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment

Secondary outcomes

  1. Number of adverse events in low-risk and intermediate-risk patients

    According to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: From enrollment to end of therapy (approximately 8 months

  2. Number of adverse events in high-risk patients

    According to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: From enrollment to end of therapy (approximately 8 months

  3. Local failure rate

    Local failure rate in irradiated and non-irradiated patients

    Time frame: From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment

  4. Event-free survival

    Time to event defined as relapse, progression or death. The EFS for the low-risk patients and intermediate-risk patients are compared to those in HOD08 and HOD05, respectively.

    Time frame: From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment

  5. Response rate

    Response rate of adequate response after 2 cycles of AEPA in the high-risk patients with FDG-PET compared to that after 2 cycles of AEPA in HLHR13.

    Time frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment

  6. Response rate

    Response rate of adequate response after 2 cycles of BEABOVP in the low-risk and high-risk patients with FDG-PET compared to those after 2 cycles of STANFORD V chemotherapy in HOD08 and HOD05, respectively.

    Time frame: after the first 2 cycles of chemotherapy (at approximately 2 months after enrollment

  7. Event-free survival

    Time to event defined as relapse, progression or death. The EFS for the high-risk patients is compared to those in HLHR13.

    Time frame: From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment

07

Study locations

8 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Jan 2027, 96 months after the start.

Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's planned 96 months is above that.

Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Nov 28, 2018
StartActual
Dec 12, 2018
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03755804
Responsible party
Sponsor
First posted
Nov 28, 2018
Start date
Dec 12, 2018
Primary completion
Jan 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Matthew Ehrhardt, MD, MS
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Bleomycin · Vincristine · Vinblastine · Brentuximab Vedotin · Cyclophosphamide · Dacarbazine

Start the discussion